| Investor Type | Firm |
| Type of Fund | Corporate VC |
| Stages | Seed |
| Investment Range | €250,000 - €1,000,000 |
Synergy Ventures is a Corporate VC firm based in the USA specializing in seed investments, primarily focusing on start-up companies developing medical device and diagnostic products. With an investment range of $250,000 to $1,000,000, their interest lies in innovative enterprises that are creating solutions for major diseases and conditions which are becoming increasingly prevalent in industrialized countries due to aging populations.
This encompasses medical challenges such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. Their investment thesis hinges on backing startups with novel, single-use medical devices that offer clinically efficacious therapy at a reduced cost, coupled with manageable regulatory and reimbursement risks.
Particularly, they target ventures that have product concepts capable of advancement with minimal infrastructure and which can demonstrate the clinical efficacy of their product or technology at an early stage, thereby establishing a strong foundation for future partnerships and acquisitions.
Synergy Ventures is not just an investor; they actively assist their portfolio companies in forging corporate partnerships in Japan when the time is ripe, facilitating significant strategic and economic advantages. They have established connections with major Japanese medical device corporations, which also serve as their limited partners (LPs).
Moreover, through their sister company, Synergy Partners International, they aid clients in developing investment and strategic partnering relationships between U.S. medical technology companies and Japanese corporations looking to expand their medical business segments.
We invest in start-up companies developing medical device and diagnostic products that address major diseases and conditions prevalent in industrialized countries as the population ages (such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders). In these areas, we favor companies with novel, single-use medical devices that can provide clinically efficacious therapy, at lower cost, and with manageable and acceptable regulatory and reimbursement risks. We look for start-up ventures featuring product concepts that can be advanced with minimal infrastructure and head-count – companies that can demonstrate clinical efficacy of their product or technology early on, and thus create strong potential for partnerships and acquisitions. Synergy also assists our portfolio companies in developing corporate partnerships in Japan at the appropriate time, which can also provide significant strategic and economic benefits. Our LPs are major Japan medical device corporations.









